Sebastian Meerwein
Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study.
Fleischmann R, Meerwein S, Charles-Schoeman C, Combe B, Hall S, Khan N, Carter K, Camp H, Rubbert-Roth A. Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study. RMD Open 2024; 10
Jul 25, 2024Efficacy and safety of upadacitinib in patients with rheumatoid arthritis and inadequate response or intolerance to biological treatments: results through 5 years from the SELECT-BEYOND study.
Jul 25, 2024RMD Open 2024; 10
Fleischmann Roy, Meerwein Sebastian, Charles-Schoeman Christina, Combe Bernard, Hall Stephen, Khan Nasser, Carter Kyle M, Camp Heidi S, Rubbert-Roth Andrea
Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial
Genovese M, Meerwein S, Mohamed M, Zhou Y, Zhang Y, Rubbert-Roth A, Hall S, Combe B, Fleischmann R, Pangan A. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial. Lancet 2018; 391:2513-2524.
Jun 18, 2018Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial
Jun 18, 2018Lancet 2018; 391:2513-2524
Genovese Mark C, Meerwein Sebastian, Mohamed Mohamed-Eslam F, Zhou Yijie, Zhang Ying, Rubbert-Roth Andrea, Hall Stephen, Combe Bernard, Fleischmann Roy, Pangan Aileen L